Clinical Trial Update: A Single Arm, Tolerability and Safety Phase IV Study of Fulvestrant(Faslodex® ) as 2nd Line and Later Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer [Phase 4]

View source ↗

Summary

Phase IV single-arm trial assessing tolerability and safety of fulvestrant as 2nd line and later therapy in postmenopausal women with locally advanced or metast…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Faslodex (fulvestrant)

Snippet

Sponsor: AstraZeneca | Conditions: Locally Advanced or, Metastatic Breast Cancer | Phase 4 | Status: COMPLETED | Results posted: 2018-03-22